Rotigotine is a non-selective dopamine agonist used for the treatment of Parkinson's Disease and Restless Leg Syndrome. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours.
- Mechanism
- Curator reviewed
Rotigotine, a member of the dopamine agonist class of drugs, is delivered continuously through the skin (transdermal) using a silicone-based patch that is replaced every 24 hours. A dopamine agonist works by activating dopamine receptors in the body, mimicking the effect of the neurotransmitter dopamine. The precise mechanism of action of rotigotine as a treatment for Restless Legs Syndrome is unknown but is thought to be related to its ability to stimulate dopamine
- Primary indication
- For use/treatment in neurologic disorders and parkinson's disease as well as moderate-to-severe primary Restless Legs Syndrome.Curator reviewed · 3 structured indications
- Formula / weight
- C19H25NOS · 315.48 g/mol (avg)
- First approval
- Canada, 2013 · United States, 2012 · European Union, 2021
- Code names
- N-0923 · SPM 962
- Brand names
Resolves to
KFQYTPMOWPVWEJ-INIZCTEOSA-NSMILESCCCN(CCC1=CC=CS1)[C@H]1CCC2=C(O)C=CC=C2C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Rotigotine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account